Financial Performance

2021 was a year in which we set all-time highs in several
financial categories - including Revenue and Adjusted Diluted EPS

Financial Performance

Three-year summary for the years ended December 31

Millions (Except Per Common Share Data)
% Change
20212020201921/2020/19

Revenues

$81,288

$41,651

$40,905

95

2

Reported net income (1)

$21,979

$9,159

$16,026

*

(43)

Reported diluted EPS (1)

$3.85

$1.63

$2.82

*

(42)

Adjusted income (2)

$25,236

$12,727

$11,056

98

15

Adjusted diluted EPS (2)

$4.42

$2.26

$1.95

96

16

Net cash provided by operating activities

$32,580

$14,403

$12,588

*

14

Cash dividends paid

$8,729

$8,440

$8,043

3

5

  1. Reported net income is defined as Net income attributable to Pfizer Inc. common shareholders in accordance with U.S. GAAP. Reported diluted earnings per share (EPS) is defined as EPS attributable to Pfizer Inc. common shareholders—diluted in accordance with U.S. GAAP.

  2. Adjusted income and Adjusted diluted EPS are defined as U.S. GAAP Net income attributable to Pfizer Inc. common shareholders and reported EPS attributable to Pfizer Inc. common shareholders—diluted before the impact of purchase accounting for acquisitions, acquisition-related items, discontinued operations and certain significant items. The Adjusted income and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and diluted EPS, have no standardized meaning prescribed by U.S. GAAP and may not be comparable to the calculation of similar measures of other companies. See the Non-GAAP Financial Measure: Adjusted Income section of Management's Discussion and Analysis of Financial Condition and Results of Operations(link is external) in Pfizer’s 2021 Annual Report on Form 10-K for an explanation of how management uses these non-GAAP measures, reconciliations to the most directly comparable GAAP measures and additional information.

Detailed information on our financial and operational performance can be found in our 2021 Annual Report on Form 10-K.

Top 10 Medicines and Vaccines

Take a look at our breakdown of the top medicines and vaccines by revenue from 2021.

  • $36,781 million
    Comirnaty®
  • $5,970 million
    Eliquis® (apixaban)
  • $5,437 million
    Ibrance® (palbociclib)
  • $5,272 million
    Prevnar Family®
  • $2,455 million
    Xeljanz® (tofacitinib)
  • $2,015 million
    Vyndaqel®/Vyndamax™ (tafamidis)
  • $1,185 million
    Enbrel® (etanercept)
  • $1,185 million
    Xtandi® (enzalutamide)
  • $1,002 million
    Inlyta® (axitinib)
  • $683 million
    Sulperazon® (sulbactam sodium/cefoperazone sodium)
A circle graph illustrating the top 10 Pfizer medicines and vaccines by revenue in 20212021 Revenue